返回 
加入收藏
干扰素α1b与α2b治疗慢性丙型肝炎的最小成本分析
x
请在关注微信后，向客服人员索取文件
| 篇名： | 干扰素α1b与α2b治疗慢性丙型肝炎的最小成本分析 |
| TITLE： | |
| 摘要： | 目的：比较干扰素α1b与α2b治疗慢性丙型肝炎的经济性。方法：采用回顾性研究方法，选择114例接受干扰素治疗的慢性丙型肝炎患者，将其中采用干扰素α1b治疗的60例作为A组，采用干扰素α2b治疗的54例作为B组，比较两组患者的丙型肝炎病毒（HCV）-RNA转阴率、丙氨酸转氨酶（ALT）复常率和不良反应发生率，并进行药物经济学分析。结果：A组患者治疗4、12、24、36、48周时的HCV-RNA转阴率分别为55.00％、71.67％、63.33％、61.67％、65.00％，B组患者在上述各时间的HCV-RNA转阴率分别为64.81％、66.67％、62.96％、55.56％、61.11％，组间比较差异均无统计学意义（P＞0.05）；治疗结束时，A组患者的ALT复常率为95.23％，B组为96.10％，组间比较差异无统计学意义（P＞0.05）；两组患者各种不良反应发生率比较，差异均无统计学意义（P＞0.05），故采用最小成本法进行药物经济学分析。A组的治疗成本为13 216.56元，B组为7 929.60元，B组的成本明显低于A组；敏感度分析得到同样的结果。结论：干扰素α2b治疗慢性丙型肝炎较干扰素α1b更为经济。 |
| ABSTRACT： | OBJECTIVE： To compare the economics of interferon α1b and α2b in the treatment of chronic hepatitis C. METHODS： By retrospective study， 114 patients with chronic hepatitis C who received interferon were selected， 60 patients received interferon α1b were divided into group A and 54 patients received interferon α2b were divided into group B. Negative conversion rate of HCV-RNA， normalization rate of ALT and the incidence of ADR in 2 groups were compared， and pharmacoeconomic analysis was conducted. RESULTS： Negative conversion rates of HCV-RNA in group A in 4， 12， 24， 36， 48 weeks were 55.00％， 71.67％， 63.33％， 61.67％ and 65.00％，group B were 64.81％， 66.67％， 62.96％， 55.56％ and 61.11％， respectively， there were no significant differences between 2 groups （P＞0.05）； after treatment， normalization rate of ALT in group A was 95.23％， group B was 96.10％， there was no significant difference between 2 groups （P＞0.05）； and there were no significant differences in the incidence of ADR between 2 groups （P＞0.05）， so cost-minimization analysis was used to evaluate pharmacoeconomics. Therapy cost in group A was 13 216.56 yuan， group B was 7 929.60 yuan， group B was lower to group A； sensitivity analysis received the same results. CONCLUSIONS： Interferon α2b is more economical than α1b in the treatment of chronic hepatitis C. |
| 期刊： | 2016年第27卷第23期 |
| 作者： | 张明明，吕飞，徐一丹，郑莉，余行，李燕，张鸿 |
| AUTHORS： | ZHANG Mingming，LYU Fei，XU Yidan，ZHENG Li，YU Xing，LI Yan，ZHANG Hong |
| 关键字： | 干扰素α1b；干扰素α2b；慢性丙型肝炎；药物经济学；最小成本分析 |
| KEYWORDS： | Interferon α1b； Interferon α2b； Chronic hepatitis C； Pharmacoeconomics； Cost-minimization analysis |
| 阅读数： | 351 次 |
| 本月下载数： | 6 次 |
* 注：未经本站明确许可，任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作！
